GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Uproleselan showed significant improvement in median overall survival (31.2 months) for primary refractory AML patients compared to placebo (10.1 months). Adverse events aligned with chemotherapy profiles. GlycoMimetics plans further studies with NCI and Alliance for Clinical Trials in Oncology, focusing on frontline AML in older adults.